Updated from 6:56 a.m. EDT
reported first-quarter net income rose 24% to $1.31 billion, or $1.20 a share, topping analysts' estimates of 99 cents a share as total revenue rose 5% to $5.05 billion.
In the year-earlier first quarter, the health care company reported earnings of $1.06 billion, or 97 cents a share, on sales of $4.81 billion.
The company reconfirmed its 2009 financial guidance, including earnings guidance of $4 to $4.25 a share. Analysts expect earnings of $4.14 a share.
The drugmaker said its first-quarter profits rose on a boost in sales of the antidepressant Cymbalta and the insulin Humalog as costs fell.
Higher prices for several drugs also helped revenue.
Copyright 2008 TheStreet.com Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. AP contributed to this report.